Risk Factors for Cervical Precancer and Cancer in HIV-Infected, HPV-Positive Rwandan Women

Kathryn Anastos1*, Donald R. Hoover2, Robert D. Burk3, Antonio Cajigas4, Qihu Shi5, Diljeet K. Singh6, Mardge H. Cohen7, Eugene Mutimura8, Charles Sturgis9, William C. Banzhaf10, Philip E. Castle11

1 Departments of Medicine and Epidemiology and Population Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America, 2 Department of Statistics and Institute for Health, Health Care Policy and Aging Research, Rutgers University, Piscataway, New Jersey, United States of America, 3 Division of Genetics, Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, United States of America, 4 Department of Pathology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America, 5 Department of Epidemiology and Community Health, New York Medical College, Valhalla, New York, United States of America, 6 Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, 7 John Stroger (formerly Cook County) Hospital and Rush University, Chicago, Illinois, United States of America, 8 Women’s Equity in Access to Care and Treatment, Kigali, Rwanda, 9 Providence Regional Medical Center, Everett, Washington, United States of America, 10 University of Chicago Pritzker School of Medicine, Evanston, Illinois, United States of America, 11 National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America

Abstract

Background: Although cervical cancer is an AIDS-defining condition, infection with human immunodeficiency virus (HIV) may only modestly increase the risk of cervical cancer. There is a paucity of information regarding factors that influence the natural history of human papillomavirus (HPV) in HIV-infected women. We examined factors associated with cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) in Rwandan women infected with both HIV and HPV (HIV+/HPV+).

Methods: In 2005, 710 HIV+ Rwandan women ≥25 years enrolled in an observational cohort study; 476 (67%) tested HPV+. Each woman provided sociodemographic data, CD4 count, a cervical cytology specimen and cervicovaginal lavage (CVL), which was tested for >40 HPV genotypes by MY09/MY11 PCR assay. Logistic regression models calculated odds ratios (OR) and 95% confidence intervals (CI) of associations of potential risk factors for CIN3+ among HIV+/HPV+ women.

Results: Of the 476 HIV+/HPV+ women 42 (8.8%) were diagnosed with CIN3+. Factors associated with CIN3+ included ≥7 (vs. 0-2) pregnancies, malarial infection in the previous six months (vs. never), and ≥7 (vs. 0-2) lifetime sexual partners. Compared to women infected by non-HPV16 carcinogenic HPV genotypes, HPV16 infection was positively associated and non-carcinogenic HPV infection was inversely associated with CIN3+. CD4 count was significantly associated with CIN3+ only in analyses of women with non-HPV16 carcinogenic HPV (OR = 0.62 per 100 cells/mm3, CI = 0.40-0.97).

Conclusions: In this HIV+/HPV+ population, lower CD4 was significantly associated with CIN3+ only in women infected with carcinogenic non-HPV16. We found a trend for higher risk of CIN3+ in HIV+ women reporting recent malarial infection; this association should be investigated in a larger group of HIV+/HPV+ women.

Citation: Anastos K, Hoover DR, Burk RD, Cajigas A, Shi Q, et al. (2010) Risk Factors for Cervical Precancer and Cancer in HIV-Infected, HPV-Positive Rwandan Women. PLoS ONE 5(10): e13525. doi:10.1371/journal.pone.0013525

Editor: Beatriz Grinsztejn, Instituto de Pesquisa Clinica Evandro Chagas, FIOCRUZ, Brazil

Accepted September 1, 2010; Published October 20, 2010

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

Funding: This study was supported by supplements from the National Institute of Allergy and Infectious Diseases and the National Cancer Institute to the Bronx/Fed and the Center for AIDS Research at Montefiore Medical Center funded by the National Institutes of Health (NIH AI-51519) and by the National Institute of Diabetes and Digestive and Kidney Disease (DK54615). Dr. Castle was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: kanastos@verizon.net

Introduction

Cervical infections by carcinogenic human papillomavirus (HPV) genotypes cause virtually all cervical cancer and its immediate precursor lesion, cervical intraepithelial neoplasia grade 3 (CIN3) [1–3]. Exposure to genital HPV is nearly universal in sexually active people but the majority of infections clear within 1–2 years [4–6]. Persistence in women of a carcinogenic HPV type (HR-HPV) increases the risk of cervical intraepithelial neoplasia grade 3 (CIN3) and cancer [7]. A significant proportion of CIN3 will invade if not detected and treated [8].

Evidence suggests that secondary factors, or HPV cofactors, influence the progression of HR-HPV infections to CIN3 and cancer (CIN3+), including exogenous factors such as parity, smoking tobacco and possibly oral contraceptive use [9]. Co-infection by human immunodeficiency virus (HIV) may moderately increase the risk of cervical cancer [10], as immunosuppression may compromise the ability of the host to clear the HPV infection. The lack of a more profound impact of HIV on cervical cancer rates may be explained by two findings: 1) the early natural history of HPV16, the HPV genotype most often associated with progression to carcinoma, appears to be minimally affected by the
severity of immunosuppression, suggesting it may more effectively escape immune surveillance even in an immunocompetent host [11–13]; and 2) increasing severity of immunosuppression only modestly increases the likelihood of HPV persistence [12]. However, there is a paucity of information regarding factors that influence the natural history of HPV in HIV-infected women.

We conducted a cross-sectional analysis of risk factors associated with CIN3 and cancer in a population of HIV-infected Rwandan women. We previously found in this population that HPV prevalence and presence of cytologic abnormalities were inversely associated with CD4 cell counts [13]. We limited the study population to HIV-infected women with prevalent HPV, since HR-HPV infection is required for the development of CIN3. CIN3 was our primary endpoint because CIN3 is the best surrogate for cancer risk and while CIN2 is the clinical threshold for treatment, it is a poorly reproducible diagnosis of cervical precancer [14–17].

Methods

Ethics Statement

Each participant provided written informed consent after viewing a video demonstrating study procedures. The Rwanda National Ethics Committee and the Institutional Review Board of Montefiore Medical Center, Bronx, NY approved the study protocol and the consent process.

Participants

The Rwanda Women’s Interassociation Study and Assessment (RWISA) is an observational cohort study of 710 HIV-infected and 226 HIV-uninfected Rwandan women enrolled May-November, 2005. Methods have been previously described in detail [13]. This analysis includes the 476 women co-infected with HIV and HPV (HIV+/HPV+). At study entry, participants provided historical information on sociodemographic characteristics, physical examination was performed, and blood specimens were taken for CD4 cell count, full blood count, and other laboratory testing.

Participants underwent pelvic examinations. To minimize contamination of gynecologic specimens by blood, exfoliated cervical cells (used for HPV DNA testing) were obtained by cervicovaginal lavage (CVL) prior to collection of a cervical cytology specimen, as previously described [13]. Colposcopy was provided to all women with any abnormal cytologic finding including atypical cells of uncertain significance and cervical biopsies were obtained for specific clinical indications: any visible lesion, suspected malignancy, or cytologic interpretation of high-grade squamous intraepithelial lesions (HSIL), atypical squamous cells of uncertain significance with suspicion of HSIL, atypical glandular cells, or cancer.

Clinical Laboratory Data

CD4 counts were measured at the National Reference Laboratory of Rwanda by FACS Count (Becton Dickinson, San José, CA).

HPV Testing

HPV testing was performed on CVL specimens taken at the enrollment visit.

In brief, 100 μL of each CVL specimen was mixed (1:1) with a 2× solution of K buffer (containing Proteinase K at 400 g/mL, 2 mM EDTA, 2% Laureth-12, 100 mM Tris, pH 8.5) and incubated at 55°C for 2 hours followed by a further incubation at 95°C for 10 minutes. After the CVL specimens were digested with Proteinase K, 10 μL of each cell digest was taken to detect HPV DNA using the L1 MY09/MY11 modified PCR system with AmpliTaq Gold polymerase as described elsewhere [16]. Amplification products were probed for the presence of any HPV DNA by Southern blot with a radiolabeled generic probe mixture and subsequently typed by dot blot hybridization for HPV 6, 11, 13, 16, 18, 26, 31–35, 39, 40, 42, 45, 51–59, 62, 64, 66–74, 81–85, 89, and 97. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 were considered the primary carcinogenic HPV genotypes.

Histopathology

Biopsies and excised tissue were read independently and blindly by pathologists at Montefiore Medical Center in the Bronx, New York or Evanston Hospital in Chicago Illinois, and were categorized as Negative, CIN1, CIN2, CIN3, and cancer. We used the most severe histopathologic diagnosis as the final participant diagnosis. Among the 202 biopsies, 3 were diagnosed as cancer, 39 CIN3, 21 CIN2, and 76 CIN1.

Statistical Analysis

Of the 710 HIV-infected women 476 (67.0%) tested positive for any HPV DNA. Although non-carcinogenic HPV has not been shown to be a cause of cervical cancer, we included those women positive for non-carcinogenic HPV because some HPV genotypes categorized as non-carcinogenic HPV may be borderline carcinogenic [19] and may cause CIN3 (with little chance of invasion) particularly in HIV+ women [20]. We performed analyses on all HPV+ women, women with carcinogenic HPV genotypes and women with carcinogenic HPV genotypes other than HPV16.

Standard contingency table methods, with exact tests and when appropriate Mantel extension trend tests assessed univariate associations of categorical variables with CIN3 and cancer versus <CIN3. Two-sided P values <0.05 were considered statistically significant. The associations of ordinaly categorized continuous variables with grade of neoplasia were assessed with logistic regression and trend tests. Odds ratios (OR) and 95% confidence intervals (CI) adjusted for variables identified in univariate analyses were calculated using logistic regression. Multivariate logistic regression models were fit using variables that had statistically significant (P ≤ 0.05) unadjusted associations with CIN3+ and women that had complete information on these variables: 454 of 476 (95.4%) women positive for any HPV; 303 of 316 (95.9%) positive for carcinogenic HPV; and 241 of 251 (96.0%) women with non-16 carcinogenic HPV. Because of the relationship of CD4 counts with immunosuppression, all models included CD4 counts. We repeated these analyses with the outcome defined as CIN2 or more severe (CIN2+), including 21 women with CIN2, an equivocal precancer diagnosis.

Results

Demographic and clinical characteristics of the included women are shown in Table 1. Of the 476 HPV+ women, 223 had a colposcopy and 292 had a cervical biopsy. Among women diagnosed with CIN3+ (n = 42; 39 CIN3, 3 cancer) the most common HPV types detected were HPV16 (33%), HPV58 (26%), HPV31 and 33 (21% each) and HPV 35 and 51 (19% each). HPV32 was harbored by 4.8% and 64.3% were infected with multiple HPV types, compared to 11.1% and 49.8% of women with <CIN3, respectively. Compared to women with a less severe histologic diagnosis, women diagnosed with CIN3+ reported more pregnancies (p trend ≤ 0.001) and lifetime sexual partners (p trend = 0.03), shared their residence with more people (p trend = 0.01), had a higher income (p trend = 0.02), were more likely to have a...
Table 1. Demographic and clinical characteristics in human immunodeficiency virus-infected, human papillomavirus (HPV)-infected women with and without cervical intraepithelial neoplasia grade 3 (CIN3) or cancer (CIN3+).

|                          | All (N = 476) | CIN3+ (n = 42) | <CIN3 (n = 434) | CIN3+ vs. <CIN3 |
|--------------------------|--------------|---------------|----------------|----------------|
|                          | N  | %  | n  | %  | n  | %  | p    | ptrend |
| **Age Category (Years)** |    |    |    |    |    |    |      |        |
| 25–34                    | 285 | 60% | 22 | 52% | 263 | 61% | 0.47 | 0.74   |
| 35–44                    | 151 | 32% | 18 | 43% | 133 | 31% |      |        |
| 45–54                    | 37  | 8%  | 2  | 5%  | 35  | 8%  |      |        |
| 55+                      | 3   | 1%  | 0  | 0%  | 3   | 1%  |      |        |
| **Number of Pregnancies**|    |    |    |    |    |    |      |        |
| 0–2                      | 199 | 42% | 8  | 19% | 191 | 44% | 0.0002 | 0.0001 |
| 3–4                      | 179 | 38% | 20 | 48% | 159 | 37% |      |        |
| 5–6                      | 62  | 13% | 5  | 12% | 57  | 13% |      |        |
| ≥7                       | 31  | 7%  | 9  | 21% | 22  | 5%  |      |        |
| **Number of Sexual Partners, Lifetime** |    |    |    |    |    |    |      |        |
| 1–2                      | 145 | 30% | 10 | 24% | 135 | 31% | 0.065 | 0.026  |
| 3–4                      | 145 | 30% | 8  | 19% | 137 | 32% |      |        |
| 5–6                      | 74  | 16% | 10 | 24% | 64  | 15% |      |        |
| ≥7                       | 105 | 22% | 14 | 33% | 91  | 21% | 0.42  | n/a    |
| **Marital Status**       |    |    |    |    |    |    |      |        |
| Married                  | 58  | 12% | 7  | 17% | 51  | 12% |      |        |
| Unmarried, with partner  | 110 | 23% | 12 | 29% | 98  | 23% |      |        |
| Widowed                  | 185 | 39% | 16 | 38% | 169 | 39% |      |        |
| Separated/Divorced       | 119 | 25% | 7  | 17% | 112 | 26% |      |        |
| **Oral Contraceptive Use**|    |    |    |    |    |    |      |        |
| Never Used               | 408 | 88% | 32 | 74% | 376 | 87% | 0.075 | n/a    |
| Ever Used                | 57  | 12% | 9  | 21% | 48  | 11% |      |        |
| **Number of Gynecologic Infections** |    |    |    |    |    |    |      |        |
| 0                        | 123 | 26% | 9  | 21% | 114 | 26% | 0.73  | 0.81   |
| ≥1–2                     | 322 | 68% | 31 | 74% | 291 | 67% |      |        |
| ≥3                       | 23  | 5%  | 1  | 2%  | 22  | 5%  |      |        |
| **Number of People in Residence** |    |    |    |    |    |    |      |        |
| 1–2                      | 149 | 31% | 7  | 17% | 142 | 33% | 0.083 | 0.013  |
| 3–4                      | 92  | 19% | 8  | 19% | 84  | 19% |      |        |
| 5–6                      | 143 | 30% | 14 | 33% | 129 | 30% |      |        |
| ≥7                       | 84  | 18% | 12 | 29% | 72  | 17% |      |        |
| ≥350                     | 104 | 22% | 7  | 17% | 97  | 22% | 0.76  | 0.61   |
| 200–349                  | 178 | 37% | 17 | 40% | 161 | 37% |      |        |
| <200                     | 192 | 40% | 17 | 40% | 175 | 40% |      |        |
| **Income (Rwandan Francs)** |    |    |    |    |    |    |      |        |
| <10K                     | 166 | 35% | 9  | 21% | 157 | 36% | 0.055 | 0.017  |
| >10K–≤35K                | 233 | 49% | 22 | 52% | 211 | 49% |      |        |
| >35K                     | 66  | 14% | 10 | 24% | 56  | 13% |      |        |
| **Current Health Insurance** |    |    |    |    |    |    |      |        |
| Yes                      | 209 | 45% | 23 | 55% | 186 | 43% | 0.19  | n/a    |
| No                       | 260 | 55% | 19 | 45% | 241 | 56% |      |        |
| **Number of Meals with Meat (weekly)** |    |    |    |    |    |    |      |        |
| 0                        | 240 | 50% | 15 | 36% | 225 | 52% | 0.1   | 0.14   |
| ≥1–2                     | 152 | 32% | 19 | 45% | 133 | 31% |      |        |
| ≥3                       | 74  | 16% | 7  | 17% | 67  | 15% | 0.096 | 0.047  |
| **Malarial Infection**   |    |    |    |    |    |    |      |        |
| Never                    | 86  | 18% | 3  | 7%  | 83  | 19% |      |        |
| Past                     | 205 | 43% | 19 | 45% | 186 | 43% |      |        |
| Recent                   | 176 | 37% | 20 | 48% | 156 | 36% |      |        |
| **HPV DNA Status**       |    |    |    |    |    |    |      |        |
| Non-Carcinogenic         | 160 | 34% | 4  | 10% | 156 | 36% |      |        |
| Carcinogenic HPV (excluding HPV16) | 251 | 53% | 24 | 57% | 227 | 52% |      |        |
| HPV16                    | 65  | 14% | 14 | 33% | 51  | 12% |      |        |
| Multiple HPV types        | 243 | 51% | 27 | 64% | 216 | 50% | 0.077 | n/a    |

*Self-reported; includes incidences of rape; n/a = not applicable.

doi:10.1371/journal.pone.0013525.t001
recent malarial infection (p_trend = 0.047) and to harbor carcinogenic HPV (p_trend < 0.001). CD4 counts were not related to cervical histologic findings among all HIV+/HPV+ women.

The results of the three logistic regression models are shown in Table 2. Of the 476 HPV+ women, 65 (14%) had HPV16, 251 (53%) had carcinogenic HPV other than HPV16, and 160 (34%) had only non-carcinogenic HPV. Among all HIV+/HPV+ women, factors significantly associated with a histologic diagnosis of CIN3+ included 7 or more (vs. 0-2) pregnancies (OR = 8.7; CI 2.3-32.4), malarial infection in the previous six months (vs. never) (OR 3.9; CI 1.0-15.2), and 7 or more lifetime sexual partners (vs. 1–2 partners) (OR 2.8; CI 1.1-7.2). Compared to having non-HPV16 carcinogenic genotypes, having HPV16 infection was positively associated (OR 2.6; CI 1.1-6.1) and having a non-carcinogenic HPV infection was inversely associated (OR 0.26; CI 0.09-0.81) with CIN3+ (vs. a less severe diagnosis).

Analyses restricted to (all) carcinogenic HPV genotypes showed significant associations of CIN3+ with ≥7 pregnancies (vs. 0-2) and HPV16 (vs. non HPV16 carcinogenic genotypes). In analyses restricted to women with non-HPV16 carcinogenic HPV, ≥7 pregnancies (vs. 0-2) were associated with CIN3+. In both restricted analyses the magnitude of the associations of CIN3+ with 7 or more lifetime sexual partners and recent malarial infection were similar to that found in all HPV+ women, but were not statistically significant, perhaps because of the smaller sample sizes.

Both the magnitude (OR) and strength (p value) of the association of CD4 count with CIN3+ was greatest in the women with non-HPV16 carcinogenic HPV (Table 2): per 100 CD4 cells/ml increase, OR 0.62, CI 0.40-0.97, p = 0.035; OR 0.81, CI 0.60-1.11, p = 0.19; and OR 0.84, CI 0.63-1.12, p = 0.22 in women positive for non-HPV16 carcinogenic HPV, any carcinogenic HPV, and all HPV genotypes, respectively.

**Table 2. Multivariate associations of clinical and demographic characteristics with cervical intraepithelial neoplasia grade 3 or cancer versus less severe than CIN3 among 454 human immunodeficiency virus-infected, human papillomavirus (HPV)-infected women with complete data.**

|                   | Any HPV N = 454 | Carcinogenic HPV n = 303 | Non-HPV16 carcinogenic HPV n = 241 |
|-------------------|-----------------|--------------------------|-------------------------------|
| **Number of Pregnancies** |                 |                          |                               |
| 0–2 (ref)         | 1.00            | 1.00                     | 1.00                          |
| 3–4               | 2.58            | 1.00–6.64                | 2.27                          | 0.85–6.05 | 4.27 | 1.20–15.22 |
| 5–6               | 1.53            | 0.39–6.03                | 1.09                          | 0.23–5.05 | 0.78 | 0.07–8.25 |
| ≥7                | **8.65**        | **2.31–32.43**           | **6.82**                      | 1.67–27.97 | **7.55** | **1.26–45.18** |
| **Number of Sexual Partners** |                 |                          |                               |
| 1–2               | 1.00            | 1.00                     | 1.00                          |
| 3–4               | 0.59            | 0.20–1.74                | 0.50                          | 0.16–1.57 | 0.59 | 0.16–2.14 |
| 5–6               | 1.87            | 0.65–5.37                | 1.31                          | 0.41–4.13 | 1.14 | 0.25–5.19 |
| ≥7                | **2.76**        | **1.06–7.20**            | 2.50                          | 0.91–6.89 | 1.43 | 0.42–4.87 |
| **CD4 Count**     |                 |                          |                               |
| per 100 cells/mm³ | 0.84            | 0.63–1.12                | 0.81                          | 0.60–1.11 | **0.62** | **0.40–0.97** |
| **Number of People in Residence** |                 |                          |                               |
| 1–2 (ref)         | 1.00            | 1.00                     | 1.00                          |
| 3–4               | 1.67            | 0.52–5.27                | 1.67                          | 0.49–5.67 | 1.50 | 0.31–7.25 |
| 5–6               | 1.39            | 0.47–4.17                | 1.22                          | 0.38–3.95 | 1.61 | 0.37–7.01 |
| ≥7                | 1.59            | 0.46–5.48                | 2.04                          | 0.56–7.39 | 2.73 | 0.56–13.38 |
| **Income (Rwandan Franc)** |                 |                          |                               |
| ≤10K (ref)        | 1.00            | 1.00                     | 1.00                          |
| >10K–≤35K         | 1.55            | 0.63–3.78                | 1.37                          | 0.53–3.53 | 1.07 | 0.34–3.41 |
| >35K              | 2.16            | 0.70–6.65                | 1.36                          | 0.40–4.60 | 1.52 | 0.33–7.06 |
| **Malarial Infection** |                 |                          |                               |
| Never (ref)       | 1.00            | 1.00                     | 1.00                          |
| Past              | 2.95            | 0.75–11.63               | 2.42                          | 0.60–9.82 | 2.94 | 0.56–15.61 |
| Recent            | 3.86            | 0.98–15.24               | 3.26                          | 0.80–13.34 | 2.35 | 0.44–12.48 |
| **HPV DNA Status** |                 |                          |                               |
| Non-Carcinogenic  | **0.26**        | **0.09–0.81**            |                               |
| Carcinogenic HPV (excluding HPV16) | 1.00            | 1.00                     |                               |
| HPV16             | **2.62**        | **1.12–6.12**            | **2.93**                      | **1.24–6.89** |

OR = odds ratio; CI = 95% confidence interval; n/a = not applicable.
doi:10.1371/journal.pone.0013525.t002
As in multivariate analysis using CIN3+ as the endpoint, CIN2+ was independently and positively associated with number of pregnancies (OR 5.98, CI 1.95-17.77 for ≥7 compared to 0-2), number of sexual partners (OR 2.60, CI 1.18-5.73), and inversely associated with non-carcinogenic HPV (OR 0.25, CI 0.10-0.56). Unlike in women with CIN3+, CIN2+ was not significantly associated with harboring HPV16 (OR 1.45, CI 0.68-3.00) or with recent malarial infection (OR 1.46, CI 0.59-3.59) (data shown in Supplemental online tables S1 and S2).

Discussion

In this cross-sectional analysis of cervical histology in HIV+/HPV+ Rwandan women we found that immunosuppression as measured by CD4 count was significantly associated with CIN3+ only in women who harbored carcinogenic HPV genotypes other than HPV16. We and others have reported that HPV16 prevalence and incidence are not associated with CD4 count [12,13], suggesting that HPV16 may be more able than other HPV genotypes to avoid immune surveillance in immune competent women. Immunosuppression may differentially affect the risk of progression to CIN3 and cancer of non-HPV16 carcinogenic HPV genotypes versus HPV16, perhaps mediated directly through the likelihood of HPV viral persistence. However, we had inadequate numbers (65) of women testing positive for HPV16 to allow direct analysis of the association of CD4 count with CIN3+ in HIV+ women with HPV16 genotype.

Compared to testing positive for non-HPV16 carcinogenic HPV, CIN3+ was inversely associated with testing positive for only non-carcinogenic HPV and positively associated with testing positive for HPV16. Notably, the fraction of women with CIN3+ who tested positive for HPV16 was less than expected (33% in this study versus 50-60% in other studies) and the strength of association and magnitude of the odds ratio for the association of HPV16 with CIN3+ were smaller than anticipated. This is further albeit indirect evidence that the relative effects of HPV16 in the development of cervical cancer may be less enhanced in HIV-infected compared to uninfected women, consistent with our prior report [12]. The other AIDS-defining cancers, Kaposi's Sarcoma and large B-cell lymphoma, have demonstrated dramatically decreased incidence since the advent of effective antiretroviral therapy (ART) [21,22], which reverses much of the immune compromise of HIV infection. However, the HPV-related cancers, invasive cervical cancer and anal carcinoma, have in most reports not decreased in incidence in the era of effective ART [21–23]. This may be in part due to the lack of impact of immune suppression with HPV16 natural history, which in most populations causes at least 50% of cervical cancers.

We found that recent malarial infections had a significant positive association with CIN3+ in HIV+/HPV+ women. To our knowledge, this is the first report of any evidence that malarial infections might contribute to the risk of cervical precancer and cancer. The mechanisms by which malarial infections could increase the risk of CIN3+ are unknown, but might include additional challenges to the already compromised immune system of HIV+ women. HIV, HPV and malarial infections are highly prevalent in much of Africa, and any increased risk of CIN3+ associated with malaria could result in a substantial attributable risk. However, given the limited sample size in this analysis, this observation needs to be confirmed in other populations.

Several factors previously identified as associated with cervical precancer and cancer in general populations of women were also identified here in HIV+/HPV+ Rwandan women. We found that multiple pregnancies (7 or more) were associated with increased risk of CIN3+, independent of number of reported sexual partners. High parity has been reported as a risk factor for cancer in populations of unknown HIV serostatus [9]; the mechanism by which parity increases the risk is unknown but may be related to endogenous hormones causing further eversion of the squamouscolumnar junction and/or tissue damage and inflammation resulting from birthing. A higher number of sexual partners was also associated with CIN3+, perhaps reflecting greater likelihood of multiple HPV exposures and thus stochastically to greater opportunity for HPV persistence and progression to CIN3+.

Our study has several limitations. It is a cross-sectional analysis and temporal or causal relationships cannot be inferred. The lack of follow-up does not allow observation of progression with specific HPV types. An additional limitation of this study is that HPV+ women without clinical indication of abnormal cytology or visual lesions were not colposcoped and therefore not biopsied. Thus visually unapparent, HPV+ high-grade lesions could have been missed [24], resulting in verification bias. We expect that this may have muted the strength of association by misclassifying some cases of CIN3+ as controls. Potential misclassification of women as HPV+ may have resulted from the use of CVL rather than tissue to determine HPV infection, thus eliminating from the population women who were in fact HPV infected. It may also have led to over-representation of non-carcinogenic HPV genotypes that preferentially infect the vagina [25,26]. Further, cross-sectional detection of HPV is only a proxy for lifetime level of exposure. The smaller magnitude of the association of CIN3+ with CD4 count may not have been sufficient to achieve statistical significance because of the small number of women with HPV16. We also could not distinguish prevalent from incident infection. This may lead to underestimating the association of HR-HPV with CIN3 and cancer since prevalent infections represent a mixture of incident and persisting infections, the latter of which are on the causal pathway to cervical precancer and cancer.

In conclusion, we found that CIN3+ was inversely associated with CD4 cell count in HIV+ women co-infected with non-HPV16 carcinogenic HPV. The implication of these data is that a greater proportion of cervical precancer and cancer may be attributable to carcinogenic HPV genotypes other than HPV16 in HIV+ women compared to HIV-negative women but larger studies are needed to evaluate this directly. We also found some evidence that malarial infections may increase the risk of CIN3+; this warrants confirmation in larger population-based studies.

Supporting Information

Table S1 Demographic and clinical characteristics in human immunodeficiency virus-infected, human papillomavirus (HPV)-infected women with and without cervical intraepithelial neoplasia grade 2 or more severe (CIN2+)

Found at: doi:10.1371/journal.pone.0013525.s001 (0.11 MB DOC)

Table S2 Multivariate associations of clinical and demographic characteristics with cervical intraepithelial neoplasia grade 2 or more severe versus less severe than CIN2 among 454 human immunodeficiency virus-infected, human papillomavirus (HPV)-infected women with complete data.

Found at: doi:10.1371/journal.pone.0013525.s002 (0.07 MB DOC)
Author Contributions
Conceived and designed the experiments: KA MHC PC. Performed the experiments: KA RDB AC DKS MHC CS WCB. Analyzed the data: DRH QS. Contributed reagents/materials/analysis tools: RDB AC CS WCB. Wrote the paper: KA DRH DKS MHC EM PC.

References
1. Wallboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1): 12–9.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6): 518–27.
3. Wright TC, Jr., Schiffman M (2003) Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 348(6): 489–90.
4. Plummer M, Schiffman M, Castle PE, Maucler-Bouich D, Wheeler CM, et al. (2007) A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 195(11): 1502–9.
5. Ho GYF, Bierman R, Beardley L, CJChang, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423–428.
6. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, et al. (2008) Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100(7): 513–7.
7. Koshulj J, Lindsay L, Pimenta JM, Poole C, Jenkins D, et al. (2008) Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis. Am J Epidemiol.
8. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, et al. (2006) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9(5): 425–34.
9. Castellsague X, Munoz N (2003) Chapter 3: Cofactors in human papillomavirus carcinogenesis–role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 31: 20–6.
10. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581): 59–67.
11. Strikler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, et al. (2003) Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 95(14): 1062–71.
12. Strikler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, et al. (2003) Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 95(14): 1062–71.
13. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, et al. (2009) Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 199: 1851–61.
14. Castle PE, Stoler MH, Solomon D, Schiffman M (2007) The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses: An ALTS Report. Am J Clin Pathol 127(5): 805–15.
15. Castle PE, Schiffman M, Wheeler CM, Solomon D (2009) Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2. Obstet Gynecol 113(1): 18–25.
16. Stoler MH, Schiffman M (2001) Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285(11): 1500–3.
17. Carreon JD, Sherman ME, Guilen D, Solomon D, Herrero R, et al. (2007) CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 26(4): 441–6.
18. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, et al. (2002) Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 68(5): 417–23.
19. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens. Part B: biological agents. Lancet Oncol 10(4): 321–2.
20. Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, et al. (2008) An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol 111(4): 847–56.
21. Clifford GM, Franceschi S (2009) Cancer Risk in HIV-infected persons: influence of CD4 count. Future Oncol 5: 669–678.
22. Patel P, Hanson DL, Sollivans PS, Novak RM, Moorman Tong TC, et al. (2008) for the Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992–2003. Ann Intern Med 148: 728–736.
23. Dal Maso L, Polesiel J, Serraino D, Lise M, Piselli P, et al. (2009) Pattern of cancer risk in patients with AIDS in Italy in the HAART era. British Journal of Cancer 100: 840–847.
24. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, et al. (2004) Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 191(2): 130–4.
25. Castle PE, Schiffman M, Bratti MC, Hildesheim A, Herrero R, et al. (2004) A population based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 190(3): 458–67.
26. Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodrı´guez AC, et al. (2006) Age related changes of the cervix influence human papillomavirus type distribution. Cancer Res 66(2): 1218–24.